Skip to content
Home/Companies/Biotech/Biosergen
BI

Biosergen

Biotech·Sweden·Exited 2021·Held 8yr

Biosergen is a biotech company, headquartered in Sweden.

Entry
2013
Hold
8yr
Exit
2021
Est. EV
–

Who owns Biosergen?

Biosergen was owned by Rosetta Capital through Rosetta Capital IV (2013 vintage) from 2013 to 2021, exited via IPO.

Hand-verified · updated 2026-06-30

Rosetta Capital
Investor
Rosetta Capital
Rosetta Capital IV · 2013 · Secondaries

Key facts

HQSweden
SectorBiotech
StatusAcquired
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2021

More from Rosetta Capital IV

Other portfolio companies in the same fund.

Akinion Pharmaceuticals
Active
PharmaSweden· 2013
Aprea Therapeutics
Exited 2019
BiotechSweden· 2013
Axelar
Active
BiotechSweden· 2013
Clanotech
Active
BiotechSweden· 2013
Dilafor
Active
BiotechSweden· 2013
Inhalation Sciences
Active
MedTechSweden· 2013

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings